Steve Bryson, PhD, science writer —

Steve holds a PhD in biochemistry from the Faculty of Medicine at the University of Toronto, Canada. As a medical scientist for 18 years, he worked in both academia and industry, where his research focused on the discovery of new vaccines and medicines to treat inflammatory disorders and infectious diseases. Steve is a published author in multiple peer-reviewed scientific journals and a patented inventor.

Articles by Steve Bryson

Less dyskinesia with Duopa tied to reduced pain, improved life quality

The easing of dyskinesia — the involuntary movements associated with advanced Parkinson’s disease — seen with use of the approved medication Duopa (levodopa-carbidopa intestinal gel) was tied to reduced pain and improved health-related quality of life among patients following treatment. That’s according to a new analysis of clinical…

No tie between shingles and Parkinson’s: US veterans study

Shingles, an infectious disease marked by a painful skin rash with blisters, wasn’t associated with an increased risk of Parkinson’s disease, according to a study of more than 1 million U.S. veterans. “We showed no evidence of an increased risk of incident [Parkinson’s disease] after [shingles] in a large,…

RAZ Memory Cell Phone helps people with impaired speech

The RAZ Memory Cell Phone will allow people with impaired speech, including those with Parkinson’s disease, to speak using their own voice during video phone calls and be fully understood. The speech recognition technology was developed by Voiceitt, a voice AI and machine learning company, in partnership…

Continuous apomorphine infusion effective with advanced Parkinson’s

One year of continuous subcutaneous (under-the-skin) apomorphine infusion (CSAI) reduced the severity of advanced Parkinson’s disease among patients across India, a study showed. Disease motor symptoms, as well as various Parkinson’s nonmotor symptoms like fatigue, pain, anxiety and depression, — along with quality of life — improved…

Oral ATH434 improved motor function in monkeys

Alterity Therapeutics‘ ATH434 improved motor performance and overall function in non-human primates with induced Parkinson’s disease, according to data presented at the recent Future of Parkinson’s Disease Conference 2023. The investigational therapy is currently undergoing evaluation in an open-label biomarker study called ATH434-202 (NCT05864365), which has…